Cargando…

Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity

More than half of new cases of hepatocellular carcinoma (HCC) and associated deaths occurring annually worldwide are recorded in China. Chinese patients with HCC exhibit special characteristics in terms of etiology, leading to differences in prognosis versus Western patients. In recent years, severa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yaoqiang, Lin, Han, You, Xia, Guo, Taiyan, Sun, Tingting, Xu, Hao, Fu, Xibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960046/
https://www.ncbi.nlm.nih.gov/pubmed/35356200
http://dx.doi.org/10.3389/fonc.2022.764923
_version_ 1784677301599862784
author Wu, Yaoqiang
Lin, Han
You, Xia
Guo, Taiyan
Sun, Tingting
Xu, Hao
Fu, Xibo
author_facet Wu, Yaoqiang
Lin, Han
You, Xia
Guo, Taiyan
Sun, Tingting
Xu, Hao
Fu, Xibo
author_sort Wu, Yaoqiang
collection PubMed
description More than half of new cases of hepatocellular carcinoma (HCC) and associated deaths occurring annually worldwide are recorded in China. Chinese patients with HCC exhibit special characteristics in terms of etiology, leading to differences in prognosis versus Western patients. In recent years, several angiogenesis inhibitors were approved, and immune checkpoint blockers (ICBs) were recommended as second-line therapy for advanced HCC. In addition, the recent success of a combination of atezolizumab with bevacizumab signals resulted in an essential change in the first-line treatment of HCC. We investigated the characteristics of patients with HCC in China and summarized the rapidly emerging relevant clinical data, which relate to the prospects and challenges associated with the use of ICBs in this setting. We further evaluated the efficacy of ICBs in Chinese patients with HCC based on data obtained from global trials, and discussed possible factors influencing the effectiveness of ICBs in patients with HCC in China. Immunotherapy offers new options for the treatment of advanced HCC, though responses varied between patients. Currently, there is a need to discover specific biomarkers for the accurate identification of patients who would more likely benefit from immunotherapy. Furthermore, investigation of patient characteristics in different countries is necessary to provide a clinical practice basis and reference value for the diagnosis and treatment of HCC.
format Online
Article
Text
id pubmed-8960046
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89600462022-03-29 Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity Wu, Yaoqiang Lin, Han You, Xia Guo, Taiyan Sun, Tingting Xu, Hao Fu, Xibo Front Oncol Oncology More than half of new cases of hepatocellular carcinoma (HCC) and associated deaths occurring annually worldwide are recorded in China. Chinese patients with HCC exhibit special characteristics in terms of etiology, leading to differences in prognosis versus Western patients. In recent years, several angiogenesis inhibitors were approved, and immune checkpoint blockers (ICBs) were recommended as second-line therapy for advanced HCC. In addition, the recent success of a combination of atezolizumab with bevacizumab signals resulted in an essential change in the first-line treatment of HCC. We investigated the characteristics of patients with HCC in China and summarized the rapidly emerging relevant clinical data, which relate to the prospects and challenges associated with the use of ICBs in this setting. We further evaluated the efficacy of ICBs in Chinese patients with HCC based on data obtained from global trials, and discussed possible factors influencing the effectiveness of ICBs in patients with HCC in China. Immunotherapy offers new options for the treatment of advanced HCC, though responses varied between patients. Currently, there is a need to discover specific biomarkers for the accurate identification of patients who would more likely benefit from immunotherapy. Furthermore, investigation of patient characteristics in different countries is necessary to provide a clinical practice basis and reference value for the diagnosis and treatment of HCC. Frontiers Media S.A. 2022-03-10 /pmc/articles/PMC8960046/ /pubmed/35356200 http://dx.doi.org/10.3389/fonc.2022.764923 Text en Copyright © 2022 Wu, Lin, You, Guo, Sun, Xu and Fu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wu, Yaoqiang
Lin, Han
You, Xia
Guo, Taiyan
Sun, Tingting
Xu, Hao
Fu, Xibo
Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity
title Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity
title_full Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity
title_fullStr Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity
title_full_unstemmed Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity
title_short Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity
title_sort immune checkpoint blockade in chinese patients with hepatocellular carcinoma: characteristics and particularity
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960046/
https://www.ncbi.nlm.nih.gov/pubmed/35356200
http://dx.doi.org/10.3389/fonc.2022.764923
work_keys_str_mv AT wuyaoqiang immunecheckpointblockadeinchinesepatientswithhepatocellularcarcinomacharacteristicsandparticularity
AT linhan immunecheckpointblockadeinchinesepatientswithhepatocellularcarcinomacharacteristicsandparticularity
AT youxia immunecheckpointblockadeinchinesepatientswithhepatocellularcarcinomacharacteristicsandparticularity
AT guotaiyan immunecheckpointblockadeinchinesepatientswithhepatocellularcarcinomacharacteristicsandparticularity
AT suntingting immunecheckpointblockadeinchinesepatientswithhepatocellularcarcinomacharacteristicsandparticularity
AT xuhao immunecheckpointblockadeinchinesepatientswithhepatocellularcarcinomacharacteristicsandparticularity
AT fuxibo immunecheckpointblockadeinchinesepatientswithhepatocellularcarcinomacharacteristicsandparticularity